Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

被引：0
作者：
Javier Cortes
Amin Haiderali
Min Huang
Wilbur Pan
Peter Schmid
Katherine G. Akers
Julie E. Park
Andrew M. Frederickson
Peter A. Fasching
Joyce O’Shaughnessy
机构：
[1] International Breast Cancer Center,Oncology Department
[2] Pangaea Oncology,Faculty of Biomedical and Health Sciences, Department of Medicine
[3] Quiron Group,Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen, EMN, University Hospital Erlangen
[4] Medica Scientia Innovation Research,Baylor University Medical Center
[5] Universidad Europea de Madrid,undefined
[6] Merck & Co.,undefined
[7] Inc,undefined
[8] Barts Cancer Institute,undefined
[9] Queen Mary University of London,undefined
[10] PRECISIONheor,undefined
[11] PRECISIONheor,undefined
[12] Friedrich-Alexander University Erlangen,undefined
[13] Texas Oncology and US Oncology,undefined
来源：
BMC Cancer | / 23卷 / 1期
关键词：
Triple-negative breast cancer; Chemotherapy; Immunotherapy; Neoadjuvant therapy; PD-1; PD-L1; Network meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 211 条
[1]  
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249
[2]  
Ferlay J(2017)Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 8 1913-790
[3]  
Siegel RL(2014)New strategies for triple-negative breast cancer—deciphering the heterogeneity Clin Cancer Res 20 782-821
[4]  
Laversanne M(2020)Yu S-c: Triple-negative breast cancer molecular subtyping and treatment progress Breast Cancer Res 22 61-1100
[5]  
Soerjomataram I(2020)Pembrolizumab for Early Triple-Negative Breast Cancer N Engl J Med 382 810-1253
[6]  
Jemal A(2020)Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Lancet 396 1090-1012
[7]  
Bray F(2013)Demystifying trial networks and network meta-analysis BMJ 346 f2914-1881
[8]  
Yao H(2012)How to use an article reporting a multiple treatment comparison meta-analysis JAMA 308 1246-617
[9]  
He G(2013)Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers BMC Med 11 159-428
[10]  
Yan S(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J Clin Epidemiol 62 1006-308
12345678910